Mode
Text Size
Log in / Sign up
N/A N=392 Randomized Treatment

Individualizing Incentives for Alcohol in the Severely Mentally Ill

Schizophrenia · Bipolar Disorder · Major Depressive Disorder · Alcohol Dependence

Enrolled (actual)
392
Serious AEs
4.0%
Results posted
Aug 2025
Primary outcome: Primary: Alcohol Use Assessed by Ethyl Glucuronide (EtG) Detection in Urine — 0.66; 0.65; 0.61 proportion uEtG negative

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Usual CM (Behavioral); High-Magnitude CM (Behavioral); Shaping CM (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Washington State University
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Alcohol Use Assessed by Ethyl Glucuronide (EtG) Detection in Urine
0.66; 0.65; 0.61
SECONDARY
Positive and Negative Syndrome Scale
SECONDARY
Urinanalysis for Drug Use
SECONDARY
Addiction Severity Index (ASI)
SECONDARY
Alcohol and Cigarette Timeline Followback
SECONDARY
Fagerstrom Test of Nicotine Dependence
SECONDARY
Housing Timeline FollowBack
SECONDARY
Brief HIV Risk Behavior Scale
SECONDARY
NIH Toolbox Emotion Battery
SECONDARY
NIH Toolbox Cognition Battery
SECONDARY
Obsessive-Compulsive Drinking Scale
SECONDARY
Stimulus-Response Compatibility Task
SECONDARY
Stages of Change Readiness and Treatment Eagerness Scale
SECONDARY
Treatment Experiences and Expediencies Questionnaire

Summary

The investigators will evaluate the efficacy of a 2 various contingency management (CM) interventions (High-Magnitude CM, Shaping CM) for treating heavy drinking among individuals with serious mental illness and alcohol dependence who are seen within the context of a community mental health center setting. Participants will be 400 adults diagnosed with serious mental illness and alcohol dependence and those who demonstrate heavy drinking during the first 4 weeks will be randomized to receive treatment conditions.

Eligibility Criteria

Inclusion Criteria

  • Aged 18 to 65 years.
  • 4 or more standard drinks for females (AFAB)/ 5 or more standard drinks for males (AMAB) on 5 or more occasions in the past 30 days.
  • DSM-5 diagnosis of moderate to severe alcohol use disorder.
  • DSM-5 diagnosis of schizophrenia or schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder (>1 episode).

Exclusion Criteria

  • Current DSM-5 diagnosis of a severe substance use disorder for any substances used within the past 30 days
  • A significant risk of medically dangerous alcohol withdrawal (e.g. a history of seizures in the last 12 months, participant or clinician concern that abstinence will induce dangerous alcohol withdrawal).
  • Any medical/psychiatric condition, or severity of that condition, that in the opinion of the PI, would compromise safe study participation.
  • Inability to provide informed consent as measured by the MacCAT-CR. (e.g. dementia)
  • Pregnant or planning to become pregnant.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03481049). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search